MIRA Advances Ketamir-2 to Phase 2a for CIPN
MIRA Pharmaceuticals submitted the Phase 2a protocol for Ketamir-2 to IRB after FDA review, targeting site initiation in Q1 2027 to evaluate efficacy in chemotherapy-induced peripheral neuropathy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed